| Last Price | Today's Change | 52-Week Range | Trading Volume |
|---|---|---|---|
| 3.90 | 0.03 (+0.78%) | 2.67 - 5.07 | 118.1 thousand (Below Avg) |
Market data as of 4:01PM 06/17/13. Quotes are delayed by at least 15 min.
| Open | 3.93 |
|---|---|
| Previous Close | 3.87 |
| Day's Range | 3.85 - 3.95 |
| Market Cap | 217.3M |
| Avg Volume (10 Day) | 151.9K |
| Price/Earnings (Trailing 12 Mo.) | -- |
| Earnings Per Share (Trailing 12 Mo.) | -0.15 |
| Dividend Yield | No Dividend |


These seven metrics are a snap to calculate, thanks to Quicken.com's One-Click Scorecard. Our goal with this tool is to help you evaluate potential investment candidates and eliminate those equities that aren't up to snuff. One-Click Scorecard won't do all the homework necessary for you to reach a decision, but it will help you develop a list of quality stocks to watch and study further.
| Performed well consistently? | Fail |
|---|---|
| Avoids excess debt? | Fail |
| Converting sales to profits? | Fail |
| Shareholder's money handled rationally? | Neutral |
| Increased shareholder value? | Neutral |
| Consistently increased owner earnings? | Fail |
| Sells at 25% discount to intrinsic value? | Fail |


These eight metrics are a snap to calculate, thanks to Quicken.com's One-Click Scorecard. Our goal with this tool is to help you evaluate potential investment candidates and eliminate those equities that aren't up to snuff. One-Click Scorecard won't do all the homework necessary for you to reach a decision, but it will help you develop a list of quality stocks to watch and study further.
| Pays a cash dividend? | Fail |
|---|---|
| Room to increase dividends? | Fail |
| Increased earnings over time? | Fail |
| Borrows within reasonable limits? | Pass |
| Stock is undervalued? | Fail |
| Have investors caught on? | Fail |
| Has support of institutional investors? | Fail |
| Has sufficient liquidity? | Pass |
BioTime Appoints Henry L. Nordhoff to Board of Directors
Business Wire - Wednesday 06/12/2013 9:00 AM ET
BioTime, Inc. Closes on $9 Million Financing
Business Wire - Friday 06/07/2013 9:18 AM ET
BioTime, Inc. to Raise $9 Million in Registered Direct Offering
Business Wire - Monday 06/03/2013 4:32 PM ET
Hadasit Bio-Holdings Ltd. Portfolio Company - Cell Cure Neurosciences Ltd. Received Additional Government Support
PR Newswire - Thursday 05/23/2013 3:22 PM ET
BioTime Announces Results of Vote at Special Meeting of Shareholders
Business Wire - Thursday 05/23/2013 9:00 AM ET
BioTime CEO Dr. Michael West to Present at USC Minisymposium: Musculoskeletal Development and Repair
Business Wire - Monday 05/20/2013 9:00 AM ET
| BTX | Industry Range | |
|---|---|---|
| Revenue Growth (1yr) | -6.91% | |
| Net Income Growth (1yr) | -- | |
| Total Debt/Equity | 0.00 | |
| LT Debt/Equity | 0.00 | |
| Earnings Yield | -- | |
| Price/Sales | 55.67 |
| Company | Last | Change |
|---|---|---|
| Anacor Pharmaceuticals Inc | 4.99 | -4.95% |
| Sinovac Biotech Ltd | 3.98 | 0.00% |
| Anika Therapeutics Inc | 16.55 | +5.55% |
| Cytokinetics Inc | 1.46 | +3.55% |
| Peregrine Pharmaceuticals Inc | 1.56 | +4.00% |
Data is delayed by at least 15 min.